Lazertinib Mesylate Monohydrate

Preferred Label : Lazertinib Mesylate Monohydrate;

NCIt synonyms : Lazertinib Mesylate Hydrate; Lazertinib Mesylate;

NCIt definition : The hydrated mesylate salt form of lazertinib, an orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, with potential antineoplastic activity. Upon oral administration, lazertinib specifically and irreversibly binds to and inhibits selective EGFR mutants, specifically EGFR exon 19 deletions and exon 21 L858R substitution mutations. This prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells. In addition, lazertinib penetrates the blood-brain barrier (BBB). As this agent shows minimal activity against wild-type EGFR (wtEGFR), systemic toxicity is minimal as compared to non-selective EGFR inhibitors. EGFR, a receptor tyrosine kinase (RTK) mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.;

UNII : WUT449BEG5;

CAS number : 2411549-88-5;

Drug name : Lazcluze; Leclaza;

Details

Origin ID

C210427;

Currated CISMeF NLP mapping
- Lazertinib mesilate monohydrate [SMS substance]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Activating EGFR Gene Mutation [NCIt concept]
- EGFR Exon 19 Deletion Mutation [NCIt concept]
- EGFR NP_005219.2:p.L858R [NCIt concept]
- EGFR NP_005219.2:p.T790M [NCIt concept]
is_component_of_chemotherapy_regimen
- Amivantamab/Lazertinib Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients